Ratings Surperformance

Trader
Investor
-
Global
-
Quality
-
ESG MSCI
BBB

Ratings ESG MSCI

Ratings Axsome Therapeutics, Inc.: Strengths and Weaknesses

  • From a short-term investment perspective, the company presents a deteriorated fundamental configuration.
  • According to MSCI, the company's ESG score for its industry is poor.
Highlights: Axsome Therapeutics, Inc.
  • Analysts covering this company mostly recommend stock overweighting or purchase.
  • The difference between current prices and the average target price is rather important and implies a significant appreciation potential for the stock.
  • The average price target of analysts who are interested in the stock has been strongly revised upwards over the last four months.
  • Predictions on business development from analysts polled by Standard & Poor's are tight. This results from either a good visibility into core activities or accurate earnings releases.
Weaknesses: Axsome Therapeutics, Inc.
  • As a percentage of sales and without taking into account depreciation and amortization, the company has relatively low margins.
  • In relation to the value of its tangible assets, the company's valuation appears relatively high.
  • Revenue estimates are regularly revised downwards for the current and coming years.
  • For the past year, analysts have significantly revised downwards their profit estimates.
  • For the last twelve months, the analysts covering the company have given a bearish overview of EPS estimates, resulting in frequent downward revisions.

Rating Financials

Axsome Therapeutics, Inc. SectorUnited States

Fundamentals

-

Growth

Revenue growth

EPS growth

FCF growth

Profitability

EBITDA Margin

EBIT Margin

Net Margin

Capital Efficiency

-

ROA

ROCE

-

ROE

-

Financial Health

-

Gearing

Leverage

-

Capital Intensity

-

Balance sheet growth

Long Term balance sheet growth

-

Long term revenue growth

-

Long term EPS growth

More ratings

Rating Valuation

Axsome Therapeutics, Inc. SectorUnited States

Global Valuation

-

Enterprise Value

-

EV/Revenue

EV/EBITDA

-

EV/FCF

-

Equity Valuation

-

P/E

-

PBR

Dividend Yield

-

EV/EBIT

-

CAPEX/Revenue

More ratings

Rating Consensus

Axsome Therapeutics, Inc. SectorUnited States

Consensus

Analysts' buy/sell recommendations

Analysts' recommendations evolution (1 year)

Analysts' recommendations evolution (4 months)

Analysts' target price

Analysts' target price evolution (1 year)

Analysts' target price evolution (4 months)

Analysts' recommendations evolution (7 days)

Target Price evolution (7 days)

More ratings

Rating Business Predictability

Axsome Therapeutics, Inc. SectorUnited States

Visibility

Analysts' coverage

Financial estimates divergence

Analysts' recommendations divergence

Analysts' Target price divergence

Surprise rates

Rating Revisions

Axsome Therapeutics, Inc. SectorUnited States

Financial revisions

Revenue revisions (1 year)

Revenue revisions (4 months)

EPS revisions (1 year)

EPS revisions (4 months)

EPS revisions (7 days)

Revenue revisions (7 days)

More ratings


Capi.($) Investor ESG MSCI Fundamentals Financial revisions Global Valuation Visibility Consensus
10.62B -
BBB
- -
82.26B
BBB
61.59B -
BBB
- -
59.05B
A
51.23B
BBB
48.3B
AA
31.92B
AA
25.34B
AA
22.56B
AAA
16.56B
AA
Average 40.94B
AA
Weighted average by Cap.
AA
  1. Stock Market
  2. Stocks
  3. AXSM Stock
  4. Ratings Axsome Therapeutics, Inc.